SOUTH
SAN FRANCISCO, Calif., July 11,
2024 /PRNewswire/ -- IDEAYA Biosciences,
Inc. (Nasdaq: IDYA) today announced the closing of its
underwritten public offering of 8,355,714 shares of its common
stock at a public offering price of $35.00 per share, before underwriting discounts
and commissions, and pre-funded warrants to purchase 285,715 shares
of common stock at a public offering price of $34.9999 per pre-funded warrant, before
underwriting discounts and commissions. This includes the exercise
in full by the underwriters of their option to purchase up to an
additional 1,127,142 shares of common stock in the offering. The
gross proceeds from the offering, before deducting underwriting
discounts and commissions and other offering expenses payable by
IDEAYA, were approximately $302.4 million.
J.P. Morgan, Goldman Sachs & Co. LLC, Jefferies and RBC
Capital Markets acted as joint book-running managers for the
offering.
The public offering was made by IDEAYA pursuant to an
automatically effective shelf registration statement on Form S-3
that was previously filed with the U.S. Securities and
Exchange Commission, or the SEC. The offering was made only by
means of a written prospectus and prospectus supplement that form a
part of the registration statement. A final prospectus supplement
and accompanying prospectus relating to the offering has been filed
with the SEC and is available on the SEC's website
at http://www.sec.gov. Copies of the final prospectus
supplement and the accompanying prospectus relating to the offering
may also be obtained by request from: J.P. Morgan, by mail at J.P.
Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY
11717, or by telephone at 866-803-9204, or by email at
prospectus-eq_fi@jpmorganchase.com; Goldman Sachs & Co. LLC by
mail at Goldman Sachs & Co. LLC, Attention: Prospectus
Department, 200 West Street, New York, NY 10282, or by
telephone at 866-471-2526, or by email
at prospectus-ny@ny.email.gs.com; Jefferies, by mail at
Jefferies LLC, Attention: Equity Syndicate Prospectus Department,
520 Madison Avenue, New York, NY
10022, or by telephone at 877-547-6340 or 877-821-7388, or by email
at Prospectus_Department@Jefferies.com; or RBC Capital Markets, by
mail at RBC Capital Markets, LLC, Attention: Equity Capital
Markets, 200 Vesey Street, 8th Floor, New York, NY 10281, or by telephone at
877-822-4089, or by email at equityprospectus@rbccm.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the
discovery and development of targeted therapeutics for patient
populations selected using molecular diagnostics. IDEAYA's approach
integrates capabilities in identifying and validating translational
biomarkers with drug discovery to select patient populations most
likely to benefit from its targeted therapies. IDEAYA is applying
its research and drug discovery capabilities to synthetic lethality
– which represents an emerging class of precision medicine
targets.
Investor and Media Contact
IDEAYA
Biosciences
Andres Ruiz Briseno
Senior Vice President, Head of Finance and Investor Relations
investor@ideayabio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ideaya-announces-closing-of-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares-302195126.html
SOURCE IDEAYA Biosciences, Inc.